Episode
Ep. 305 Immune Therapy Innovations for BCG Unresponsive Cancer with Dr. Sam Chang
- Podcast
- BackTable Urology
- Published
- Jun 2, 2026
- Duration seconds
- 2938
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/BTL1628285923.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/backtable-urology-3724776/episodes/ep-305-immune-therapy-innovations-for-bcg-unresponsive-cancer-with-dr-sam-chang/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/backtable-urology-3724776/ep-305-immune-therapy-innovations-for-bcg-unresponsive-cancer-with-dr-sam-chang.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Ready to move beyond “one-size-fits-all” for BCG-unresponsive NMIBC? In this episode of BackTable Urology, Dr. Ruchika Talwar hosts Dr. Sam Chang to discuss the evolving treatment landscape for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). They explore why BCG may fail, the science and clinical rationale behind new immunotherapies and gene therapies, practical approaches to patient selection, treatment sequencing, and surveillance, and the value of emerging biomarkers, empowering urologists to make more informed, personalized decisions in complex cases of NMIBC. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by ImmunityBiohttps://anktiva.com/ --- Timestamps 00:00 - Introduction03:48 - BCG: How it Works and Why it Fails11:13 - Pembrolizumab Role and Limits14:38 - Nadofaragene firadenovec 16:34 - Cretostimogene grenadenorepvec18:39 - BCG + Anktiva Rationale29:50 - Explaining Options to Patients33:05 - Post Treatment Surveillance37:32 - Future of Biomarkers and AI42:05 - Key Takeaways --- Resources N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Reviewhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11524197/ Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancerhttps://doi.org/10.1080/2162402X.2021.1912885 IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancerhttps://evidence.nejm.org/doi/full/10.1056/EVIDoa2200167 --- More about this episode This podcast is for informational purposes only. The views and opinions expressed in this podcast are solely those of the moderator and individual guest. --- BackTable Urology is the go-to podcast fo…